ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Down 52.2% in March

ProPhase Labs, Inc. (NASDAQ:PRPH) was the target of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 793,400 shares, a decrease of 52.2% from the February 28th total of 1,660,000 shares. Based on an average trading volume of 9,120,000 shares, the short-interest ratio is currently 0.1 days. Currently, 4.2% of the shares of the stock are sold short.

ProPhase Labs Price Performance

Shares of ProPhase Labs stock traded down $0.02 during trading on Friday, reaching $0.44. The company’s stock had a trading volume of 3,276,359 shares, compared to its average volume of 2,472,609. The stock has a 50-day moving average price of $0.41 and a two-hundred day moving average price of $1.09. The stock has a market capitalization of $10.50 million, a P/E ratio of -0.35 and a beta of -0.53. The company has a current ratio of 1.47, a quick ratio of 1.33 and a debt-to-equity ratio of 0.48. ProPhase Labs has a one year low of $0.22 and a one year high of $7.48.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on ProPhase Labs in a report on Tuesday, February 25th. They set a “sell” rating for the company.

Hedge Funds Weigh In On ProPhase Labs

A number of institutional investors have recently modified their holdings of PRPH. HighTower Advisors LLC increased its holdings in shares of ProPhase Labs by 18.3% in the third quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock valued at $434,000 after purchasing an additional 27,673 shares in the last quarter. Geode Capital Management LLC boosted its position in ProPhase Labs by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock valued at $389,000 after buying an additional 13,590 shares during the last quarter. Sheets Smith Wealth Management bought a new position in ProPhase Labs in the 4th quarter valued at $158,000. SVB Wealth LLC acquired a new stake in shares of ProPhase Labs in the 4th quarter valued at $36,000. Finally, Perritt Capital Management Inc raised its position in shares of ProPhase Labs by 129.1% during the fourth quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock worth $144,000 after acquiring an additional 107,068 shares during the last quarter. 9.45% of the stock is owned by institutional investors.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.